Weight control in atrial fibrillation study
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests if a weight management program helps people with a new type of irregular heartbeat (atrial fibrillation) and obesity. It aims to see if losing weight can improve heart rhythm and reduce the need for further treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a new, persistent type of atrial fibrillation (within the past 6 months)
- You are 18 years or older
- You are obese, meaning a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition (like high blood pressure or sleep apnea)
- You are scheduled for an electrical cardioversion (a procedure to reset your heart rhythm)
- You are not currently pregnant, breastfeeding, or planning to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a weekly injection of semaglutide (the same drug in Wegovy and Ozempic) can help people with atrial fibrillation lose weight and improve their heart condition. It's for people with AF who also have obesity, and may or may not plan to have a heart procedure called catheter ablation.
This study tests whether weight loss from a medication can improve how you feel, move, and how well your heart works. It's for people who have both obesity and heart failure with reduced pumping strength.
This study compares different diets to see how they affect “arterial stiffness” (how hard the blood vessels are) in people with obesity who are starting semaglutide for weight management. It may help find a diet approach that improves heart and blood-vessel health while you use semaglutide.
This study tests if weight loss surgery can help control atrial fibrillation (an irregular heartbeat). It is for people with a BMI between 35 and 65 who have symptomatic AF and may or may not have had a prior AF procedure.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
This study tracks how semaglutide (an injectable medication that reduces appetite) helps adults lose weight in everyday life. Researchers want to understand how well it works and how safe it is for people starting the treatment.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.